ArticleJournal of medical genetics2001
beta(1)-adrenergic antagonists improve sleep and behavioural disturbances in a circadian disorder, Smith-Magenis syndrome.
Article in Journal of medical genetics, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 112 citations in OpenAlex.
- Sleep disorders in children with Smith-Magenis Syndrome - a neurodevelopmental disorder with sleep-wake-rhythm-dysfunction - recommendations for pediatricians.Sleep & breathing = Schlaf & Atmung · 2026Review
- Clinical, Sleep, and Chronobiological Characteristics of Children with Smith-Magenis Syndrome Under Treatment for Sleep Disorders.Children (Basel, Switzerland) · 2025Article
- Epigenetic Regulation and Neurodevelopmental Disorders: From MeCP2 to the TCF20/PHF14 Complex.Genes · 2024Review
- Dual orexin receptor antagonists for insomnia in youth with neurodevelopmental disorders: a case series and review.European child & adolescent psychiatry · 2023Article
- The developmental trajectory of sleep in children with Smith-Magenis syndrome compared to typically developing peers: a 3-year follow-up study.Sleep advances : a journal of the Sleep Research Society · 2023Article
- Smith-magenis syndrome: A rare case report.Journal of family medicine and primary care · 2022Article
- Caregivers' experience of sleep management in Smith-Magenis syndrome: a mixed-methods study.Orphanet journal of rare diseases · 2022Article
- Circadian disruption and human health.The Journal of clinical investigation · 2021Review
- Neurodevelopmental Disorders Commonly Presenting with Sleep Disturbances.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Review
- Review
- Smith-Magenis Syndrome: Molecular Basis of a Genetic-Driven Melatonin Circadian Secretion Disorder.International journal of molecular sciences · 2019Review
- Pediatric sleep disturbances and treatment with melatonin.Journal of translational medicine · 2019Review
- Behavior and sleep disturbance in Smith-Magenis syndrome.Current opinion in psychiatry · 2019Review
- Rhythms of life: circadian disruption and brain disorders across the lifespan.Nature reviews. Neuroscience · 2019Review
- Sleep Disorders in Childhood Neurogenetic Disorders.Children (Basel, Switzerland) · 2017Review
- Behavioral disturbance and treatment strategies in Smith-Magenis syndrome.Orphanet journal of rare diseases · 2015Article
- Neurodevelopmental Disorders Associated with Abnormal Gene Dosage: Smith-Magenis and Potocki-Lupski Syndromes.Journal of pediatric genetics · 2015Review
- Melatonin Treatment in Children with Developmental Disabilities.Sleep medicine clinics · 2015Review
- The role of nutrition and nutraceutical supplements in the treatment of hypertension.World journal of cardiology · 2014Review
- Life without double-headed non-muscle myosin II motor proteins.Frontiers in chemistry · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Smith-Magenis syndrome (SMS) is a clinically recognisable contiguous gene syndrome ascribed to interstitial deletions of chromosome 17p11.2. Patients have a phase shift of their circadian rhythm of melatonin with a paradoxical diurnal secretion of the hormone. Serum melatonin levels and day-night behaviour were studied in nine SMS children (aged 4 to 17 years) given acebutolol, a selective beta(1)-adrenergic antagonist (10 mg/kg early in the morning). Cardiac examination, serum melatonin, motor activity recordings, and sleep diaries were monitored before and after drug administration. The present study shows that a single morning dose of acebutolol suppressed the inappropriate secretion of melatonin in SMS. A significant improvement of inappropriate behaviour with increased concentration, delayed sleep onset, increased hours of sleep, and delayed waking were also noted. These results suggest that beta(1)-adrenergic antagonists help to manage hyperactivity, enhance cognitive performance, and reduce sleep disorders in SMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.